Delcath Systems, Inc. (DCTH) Posts Wider than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts DCTH Hot Sheet
Price: $13.01 -3.77%
Revenue Growth %: +9.9%
Financial Fact:
Research and development costs: 2.69M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +9.9%
Financial Fact:
Research and development costs: 2.69M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Delcath Systems, Inc. (NASDAQ: DCTH) reported Q3 loss of ($0.18), $0.04 better than the analyst estimate of ($0.22).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delcath doses first patient in breast cancer trial of Hepzato
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
